Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Hepatitis B virus (HBV) infection is a global health concern.
• Lamivudine is an antiviral nucleoside analog used to treat HBV.
• Understanding optimal dosing and duration is crucial for effective HBV management.

Purpose of the Study:

• To evaluate the efficacy and safety of three different doses of lamivudine in patients with chronic hepatitis B.
• To assess the impact of lamivudine on viral replication and liver enzyme levels.

Main Methods:

• A randomized trial involving 51 patients with chronic hepatitis B.
• Patients received lamivudine at 25 mg, 100 mg, or 300 mg daily for 24 weeks.
• A 24-week follow-up period was included to monitor viral markers and liver function.

Main Results:

• Lamivudine treatment led to decreased serum hepatitis B DNA levels across all doses, with undetectable levels in most patients at 100 mg and 300 mg.
• Normalization of elevated alanine aminotransferase (ALT) levels was observed in a significant proportion of patients, particularly at the 25 mg dose.
• Quantitative decreases in hepatitis Be antigen and hepatitis B surface antigen were noted, though viral markers often returned post-treatment.

Conclusions:

• Lamivudine demonstrated good tolerability and sustained suppression of HBV replication during the 6-month treatment period.
• The 100 mg daily dose showed promising efficacy and supports further investigation for longer treatment durations in chronic hepatitis B.
• While effective, the potential for viral marker rebound after treatment cessation warrants consideration.